A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Status:
Completed
Trial end date:
2020-01-03
Target enrollment:
Participant gender:
Summary
Evelo will investigate the safety and tolerability of EDP1066 and its potential to be a
medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and
atopic dermatitis.